Log in
Antifibrinolytic agent

Tranexamic acid

Tranexamic acid (TXA) is a synthetic lysine analog that competitively inhibits plasminogen activation, thereby preventing fibrin degradation. It is widely used to reduce blood loss in trauma, surgery, and menorrhagia. The most testable fact: TXA reduces mortality in trauma patients when given within 3 hours of injury.

Practice questionsHigh-yield facts
Drug classAntifibrinolytic (lysine analog)
MechanismInhibits plasminogen activation, prevents fibrin breakdown
Main usesTrauma hemorrhage, surgical bleeding, heavy menstrual bleeding
Key adverse effectThromboembolism (rare), seizures at high doses
7 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Tranexamic acid is a synthetic derivative of the amino acid lysine. It exerts its antifibrinolytic effect by reversibly binding to lysine-binding sites on plasminogen molecules. This competitive inhibition prevents plasminogen from binding to fibrin, thereby blocking the conversion of plasminogen to plasmin by tissue plasminogen activator (tPA).

By inhibiting plasmin formation, tranexamic acid prevents the degradation of fibrin clots and stabilizes existing hemostatic plugs. Unlike other hemostatic agents, TXA does not promote clot formation directly but rather preserves clots that have already formed. This mechanism makes it particularly useful in conditions of hyperfibrinolysis, where excessive clot breakdown contributes to ongoing bleeding.

The drug does not affect platelet function or the coagulation cascade itself, and it acts locally at sites of fibrin deposition.

High-yield for exams
  • TXA inhibits plasminogen activation by binding lysine-binding sites, preventing fibrin degradation
  • Reduces trauma mortality when given within 3 hours of injury; benefit greatest within 1 hour (CRASH-2 trial)
  • Administration after 3 hours post-trauma may increase mortality due to late fibrinolysis inhibition
  • Main adverse effects: dose-dependent seizures (especially with renal impairment), thromboembolism (rare)
  • Contraindicated in active thromboembolism, subarachnoid hemorrhage, and seizure disorders
  • Primarily renally excreted unchanged; dose adjustment required in renal impairment
  • Used in heavy menstrual bleeding, postpartum hemorrhage, and surgical bleeding prophylaxis
  • Antagonizes fibrinolytic agents (tPA); concurrent use is contraindicated

Indications

Tranexamic acid has several evidence-based indications:

Acute trauma hemorrhage

TXA reduces all-cause mortality in trauma patients with significant hemorrhage when administered within 3 hours of injury. The CRASH-2 trial established this benefit, and it is now part of major trauma protocols worldwide. Benefit is greatest when given early; administration after 3 hours may be harmful.

Surgical bleeding

TXA is used prophylactically or therapeutically to reduce blood loss in various surgeries including cardiac surgery, orthopedic procedures (especially total joint arthroplasty), and obstetric surgery (cesarean section). It decreases transfusion requirements and reoperation rates.

Heavy menstrual bleeding (menorrhagia)

Oral TXA is effective for reducing menstrual blood loss in women with objectively heavy periods. It is taken only during menses, not continuously.

Postpartum hemorrhage

The WOMAN trial demonstrated that TXA reduces death from bleeding in postpartum hemorrhage when given as adjunctive therapy with standard care.

Hereditary angioedema

TXA can be used for prophylaxis of hereditary angioedema attacks by reducing plasmin-mediated bradykinin generation.

Other indications

TXA is also used in dental procedures in patients with bleeding disorders, epistaxis, and certain cases of gastrointestinal or genitourinary bleeding.

Pharmacokinetics

Absorption: Oral bioavailability is approximately 30-50%. Peak plasma concentrations occur 2-3 hours after oral administration. Intravenous administration provides immediate drug availability.

Distribution: TXA distributes widely into most tissues. It crosses the placenta and is found in breast milk. The volume of distribution is approximately 9-12 liters. It penetrates the blood-brain barrier, which is relevant to its seizure risk.

Metabolism: Tranexamic acid undergoes minimal hepatic metabolism. Less than 5% of the drug is metabolized.

Excretion: The drug is primarily eliminated unchanged in the urine via glomerular filtration. The elimination half-life is approximately 2-3 hours in patients with normal renal function. Renal impairment significantly prolongs the half-life and requires dose adjustment.

Special populations: In patients with severe renal impairment, accumulation can occur, increasing the risk of seizures. Dose reduction is necessary when creatinine clearance is reduced.

Adverse effects

Tranexamic acid is generally well tolerated, but several adverse effects are recognized:

Common

  • Gastrointestinal disturbances: Nausea, vomiting, and diarrhea occur in approximately 10% of patients taking oral TXA. These are usually mild and dose-related.
  • Dizziness and headache: Reported with both oral and intravenous formulations.

Serious

  • Thromboembolism: The theoretical concern about increased thrombotic risk has not been consistently demonstrated in large trials when TXA is used at recommended regimens. However, caution is warranted in patients with pre-existing thrombotic risk factors. Arterial and venous thrombosis, including deep vein thrombosis, pulmonary embolism, and cerebral thrombosis, have been reported.
  • Seizures: Dose-dependent seizure risk exists, particularly at high doses or in patients with renal impairment. Seizures are more common when doses exceed recommended levels or in the setting of renal dysfunction leading to drug accumulation. This is related to CNS penetration.
  • Visual disturbances: Rare cases of visual changes and retinal vein or artery occlusion have been reported with chronic use.

Hypersensitivity

Allergic reactions including anaphylaxis are rare but possible with intravenous administration.

Cardiovascular

Hypotension can occur with rapid intravenous injection; slow administration is recommended.

Contraindications and warnings

Absolute contraindications

  • Active thromboembolic disease: Patients with acute deep vein thrombosis, pulmonary embolism, cerebral thrombosis, or other active thrombotic events should not receive TXA.
  • History of seizures: TXA lowers the seizure threshold and should be avoided in patients with epilepsy or prior seizure history when possible.
  • Hypersensitivity: Known allergy to tranexamic acid or formulation components.
  • Subarachnoid hemorrhage: TXA is contraindicated because it may increase the risk of cerebral edema and ischemia.

Relative contraindications and warnings

  • Thromboembolic risk factors: Use with caution in patients with conditions predisposing to thrombosis, including atrial fibrillation, prosthetic heart valves, prior VTE, thrombophilia, oral contraceptive use, or prolonged immobilization.
  • Renal impairment: Dose reduction is mandatory in moderate to severe renal dysfunction to prevent drug accumulation and seizure risk.
  • Disseminated intravascular coagulation (DIC): TXA should generally be avoided unless the DIC is accompanied by severe hyperfibrinolysis and other measures have failed. Expert consultation is advised.
  • Hematuria of renal origin: Upper urinary tract bleeding (renal pelvis or ureter) is a relative contraindication due to risk of ureteral obstruction from clot formation.
  • Defective color vision: TXA is contraindicated in patients with acquired defective color vision (for IV use) or any known defective color vision (for oral use) because it precludes the ability to monitor for TXA-induced retinal toxicity, which manifests as changes in color vision. Color vision testing is a key clinical endpoint used to detect retinal toxicity during chronic therapy.

Pregnancy and lactation

TXA is FDA pregnancy category B. It crosses the placenta but has been used safely in obstetric hemorrhage. The drug is excreted in breast milk in small amounts; use during breastfeeding should weigh benefits against potential risks.

Drug interactions

Tranexamic acid has relatively few significant drug interactions:

Procoagulant agents

Concurrent use with other hemostatic agents, such as factor IX complex concentrates, activated prothrombin complex concentrates (aPCC), or recombinant factor VIIa, may theoretically increase thrombotic risk. Close monitoring is advised when combination therapy is necessary.

Hormonal contraceptives and estrogens

Combined oral contraceptives and hormone replacement therapy independently increase thrombotic risk. While not an absolute contraindication, caution is warranted, and the overall risk-benefit should be assessed.

Tissue plasminogen activator (tPA) and fibrinolytic agents

TXA directly antagonizes the action of fibrinolytic drugs (alteplase, reteplase, tenecteplase, streptokinase). Concurrent use is contraindicated as TXA will negate the therapeutic effect of thrombolytics.

Tretinoin (all-trans retinoic acid)

Concurrent use with tretinoin may increase the thrombotic risk, particularly in patients being treated for acute promyelocytic leukemia.

Renal clearance interactions

Drugs that reduce renal function (NSAIDs, ACE inhibitors, aminoglycosides) may indirectly increase TXA levels by impairing its elimination, increasing seizure risk.

No significant interactions with warfarin, heparin, or direct oral anticoagulants (DOACs) have been established, though caution is advised when reversing anticoagulation in the setting of acute bleeding.

Clinical pearls

  • Timing is critical in trauma: The mortality benefit of TXA in trauma is time-dependent. Maximum benefit occurs when given within 1 hour of injury, with decreasing benefit up to 3 hours. Administration after 3 hours may increase mortality, possibly due to late inhibition of fibrinolysis needed for clot remodeling.
  • Not a replacement for surgical hemostasis: TXA is an adjunct to definitive hemorrhage control, not a substitute for surgical or procedural intervention in ongoing bleeding.
  • Seizure risk with high doses: The seizure threshold effect is dose-dependent. Seizures have been reported particularly in cardiac surgery when very high doses were used. Current protocols use lower, safer dosing regimens.
  • Monitoring: Routine coagulation studies (PT, aPTT) are not affected by TXA and are not useful for monitoring therapy. Clinical assessment of bleeding and thromboembolic signs is the primary monitoring strategy.
  • Menorrhagia dosing: For heavy menstrual bleeding, TXA is taken only during days of heavy flow, typically for up to 5 days per cycle. It is not taken continuously throughout the menstrual cycle.
  • Renal dosing adjustments: Dose reduction is essential in renal impairment to prevent accumulation and neurotoxicity.
  • Hemophilia dental procedures: TXA mouthwash or oral TXA is effective in reducing bleeding after dental extractions in patients with hemophilia, often reducing the need for factor replacement.
  • Cost-effectiveness: TXA is inexpensive and widely available, making it a highly cost-effective intervention in both high-income and low-resource settings.
  • Off-label use in hemoptysis and epistaxis: While not FDA-approved for these indications, TXA has been used successfully in refractory epistaxis and some cases of hemoptysis, particularly when topical or local hemostatic measures have failed.
Mnemonic

TXA Timing: within 3 hours for Trauma, X-tra benefit within An hour (1 hour)

Practice questions

1. A 32-year-old man is brought to the emergency department 45 minutes after a motor vehicle collision. He has multiple injuries including a pelvic fracture and is hypotensive despite fluid resuscitation. Massive transfusion protocol is activated. In addition to blood products and surgical consultation, which medication should be administered to reduce mortality?

Answer: B. Tranexamic acid given within 3 hours of traumatic injury reduces mortality from hemorrhage, with maximum benefit when given within 1 hour (CRASH-2 trial). This patient is within the therapeutic window. Vitamin K takes hours to work and is not appropriate for acute hemorrhage. Protamine reverses heparin, which is not indicated here. While aminocaproic acid has similar mechanism, TXA has the strongest evidence in trauma. Desmopressin is used for specific bleeding disorders like von Willebrand disease or uremic platelet dysfunction.

2. A 28-year-old woman presents to her gynecologist with heavy menstrual bleeding requiring pad changes every 1-2 hours during the first 3 days of her cycle. She desires future pregnancy and prefers non-hormonal management. Physical examination and pelvic ultrasound are normal. Complete blood count shows mild anemia. Which treatment is most appropriate?

Answer: C. Tranexamic acid taken only during days of heavy menstrual flow (not continuously) is an effective non-hormonal treatment for menorrhagia and preserves fertility. The patient specifically desires non-hormonal management, ruling out OCPs and the LNG-IUD. Endometrial ablation impairs fertility. Continuous TXA is not the correct regimen; it should only be taken during menses, typically for up to 5 days per cycle.

3. A 58-year-old man with a history of seizure disorder controlled on phenytoin undergoes elective total knee arthroplasty. The anesthesiologist considers administering tranexamic acid to reduce surgical blood loss. Which factor represents the strongest contraindication to TXA use in this patient?

Answer: C. A history of seizure disorder is a strong relative or absolute contraindication to tranexamic acid because TXA lowers the seizure threshold and can precipitate seizures, particularly at higher doses or with impaired renal clearance. The risk-benefit must be carefully assessed. Age over 50, elective surgery timing, and male gender are not contraindications. While phenytoin is an antiepileptic, the underlying seizure disorder itself is the concern, not drug interaction with phenytoin.

Frequently asked questions

How does tranexamic acid work?

Tranexamic acid works by binding to plasminogen and preventing its conversion to plasmin, the enzyme responsible for breaking down fibrin clots. By inhibiting plasmin formation, TXA stabilizes existing blood clots and prevents excessive bleeding in conditions of hyperfibrinolysis. It does not promote new clot formation but rather protects clots that have already formed from premature breakdown.

What are the side effects of tranexamic acid?

Common side effects include nausea, vomiting, diarrhea, dizziness, and headache. Serious but less common adverse effects include seizures (particularly at high doses or with renal impairment), thromboembolism (deep vein thrombosis, pulmonary embolism), visual disturbances, and hypotension with rapid intravenous injection. The risk of thrombosis appears low at standard recommended regimens but increases in patients with pre-existing risk factors.

When should tranexamic acid be given in trauma?

Tranexamic acid should be given as soon as possible after injury in patients with significant traumatic hemorrhage, ideally within 1 hour for maximum benefit. It can be given up to 3 hours after injury with decreasing benefit over time. Administration after 3 hours post-injury may be harmful and is generally not recommended based on CRASH-2 trial data, as late inhibition of fibrinolysis may impair necessary clot remodeling.

Is tranexamic acid safe in pregnancy?

Yes, tranexamic acid is considered relatively safe in pregnancy and is classified as FDA pregnancy category B. It crosses the placenta but extensive use in postpartum hemorrhage has not revealed significant fetal harm. The WOMAN trial demonstrated its safety and efficacy in reducing mortality from postpartum hemorrhage. It should be used when clinically indicated, as the benefits in life-threatening hemorrhage outweigh theoretical risks.

Tranexamic acid vs aminocaproic acid — what is the difference?

Both are antifibrinolytic lysine analogs that inhibit plasminogen activation, but tranexamic acid is approximately 10 times more potent than aminocaproic acid. TXA has more extensive evidence from large randomized trials, particularly in trauma and postpartum hemorrhage. Aminocaproic acid is used more commonly in the United States for cardiac surgery and certain bleeding disorders. TXA has a longer half-life and better tissue penetration, while aminocaproic acid may have a lower seizure risk at equivalent antifibrinolytic doses.

Conditions it is used for

Trauma hemorrhagePostpartum hemorrhageHeavy menstrual bleedingSurgical bleedingHereditary angioedemaEpistaxisDental bleeding in hemophiliaGastrointestinal bleeding
Aminocaproic acidAprotininDesmopressinProthrombin complex concentrateRecombinant factor VIIaVitamin KProtamine sulfateFibrinogen concentrate

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: B02AA02

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.